Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Suffix Naming Idea Trips On Dispensing Problem

Executive Summary

American Pharmacists Association tells FDA during biosimilar guidance hearing that using suffixes to create unique names will be problematic. FDA may be leaning toward the unique names, saying published literature indicates adequate safety tracking is not possible without them.

You may also be interested in...



FDA's Biosimilar Suffix 'Error': Molehill Withdrawn But Mountain Coming?

While FDA may envision suffix selection to be simple, sponsors and branding firms see a much more involved process.

Biosimilars: Zarxio Suffix Aimed At Preventing Interchangeable Confusion

FDA review documents suggest that pharmacovigilence was a significant, but secondary, concern in the naming decision.

Biosimilar Naming Is Challenge For Provider Databases

Data group says suffix construction FDA will use temporarily for its first biosimilar approval will not ensure Sandoz’s Zarxio and Amgen’s Neupogen are grouped together in provider databases.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel